Conditions:  NSCLC;  Non-small Cell Lung Cancer;  Lung Cancer;  Non-small Cell Lung Cancer Stage I;  Non-small Cell Lung Cancer Stage II;  Non-small Cell Lung Cancer Stage III;  Non-small Cell Lung Cancer Stage IIIA;  PD-L1 Gene Mutation
Interventions:  Drug: Durvalumab;  Radiation: Stereotactic Body Radiation Therapy
Sponsors:  Memorial Sloan Kettering Cancer Center;  AstraZeneca
**RECRUITING NOW**
Interventions:  Drug: Durvalumab;  Radiation: Stereotactic Body Radiation Therapy
Sponsors:  Memorial Sloan Kettering Cancer Center;  AstraZeneca
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
